目的 探讨CT灌注成像在中晚期宫颈癌化疗中的应用价值.方法 选择宫颈癌Ⅱb期以上的病例56例,化疗前行64层CT灌注扫描,记录血流量(BF)、血容量(BV)、平均通过时间(MTT)、表面通透性(PS)等参数值,并测算肿瘤大小,给予2个疗程TP方案化疗后3周行CT灌注扫描再测算宫颈癌灶大小,评价疗效.结果 BV值及PS值在完全缓解(CR)、部分缓解(PR)、病变进展(PD)、病变稳定(SD)患者间的差异有统计学意义(均P＜0.05),化疗有效患者的BV值及PS值相对较高；而BF值与MTT值在不同疗效患者间的差异无统计学意义(均P＞0.05).结论 化疗前通过CT灌注成像可测量出肿瘤的BV和PS值,从而为指导中晚期宫颈癌的治疗提供依据.%Objective To evaluate the value of CT perfusion imaging in chemotherapy for intermediate and advanced stage cancer of uterine cervix. Methods The 64-slice CT perfusion imaging was performed in 56 patients with cervical cancer stage Ⅱ b or higher before chemotherapy. The blood flow(BF),blood volume(BV) ,mean transit time(MTT) and permeability of surface (PS) were recorded and tumor size was calculated in all patients. Then enhanced CT was carried out to calculate tumor size 3 weeks after two courses of chemotherapy (TP scheme). Results There were significant differences in BV and PS among patients with complete remission,patients with partial remission, patients with progressive disease and patients with stable disease(P<0. 05). The BV and PS in patients who received effective chemotherapy were greater than those in other patients. There were no significant differences in BF and MTT among patients with different clinical outcomes(P>0. 05). Conclusion The CT perfusion imaging can measure BV and PS before chemotherapy so as to provide a basis for the treatment of intermediate and advanced stage cancer of uterine cervix.
展开▼
